529576 | InSolution™ PP2 - Calbiochem

529576
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Spec Table

      Empirical Formula
      C₁₅H₁₆ClN₅

      Pricing & Availability

      Catalogue NumberAvailability Packaging Qty/Pack Price Quantity
      529576-1MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      In Stock 
      Discontinued
      Limited Quantities Available
      Availability to be confirmed
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 1 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          Catalogue Number529576
          Brand Family Calbiochem®
          References
          ReferencesHanke, J.H., et al. 1996. J. Biol. Chem. 271, 695.



          Selected Citations
          Lee, J., et al. 2009. Cell Stem Cell 5, 76.


          Product Information
          ATP CompetitiveY
          FormClear and colorless liquid
          FormulationA 10 mM (1 mg/331 µl) solution of PP2 (Cat. No. 529573) in DMSO.
          Hill FormulaC₁₅H₁₆ClN₅
          Chemical formulaC₁₅H₁₆ClN₅
          ReversibleY
          Structure formula ImageStructure formula Image
          Applications
          ApplicationInSolution™ PP2, 172889-27-9, is a 10 mM solution of PP2 (Cat. No. 529573) in DMSO. A potent, reversible, ATP-competitive, inhibitor of the Src family of protein tyrosine kinases.
          Biological Information
          Primary Targetp56lck
          Primary Target IC<sub>50</sub>4 nM, 5 nM, 5 nM, 100 nM, against p56lck, p59fynT, Hck , and Src, respectively; 600 nM against anti-CD3-stimulated tyrosine phosphorylation of human T cells
          Purity≥95% by HPLC
          Physicochemical Information
          Cell permeableN
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          R PhraseR: 36/37/38

          Irritating to eyes, respiratory system and skin.
          S PhraseS: 23-26-36

          Do not breathe fumes.
          In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
          Wear suitable protective clothing.
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Blue Ice Only
          Toxicity Irritant
          Storage -20°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot, purge with inert gas, and freeze (-20°C).
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          529576

          References

          Reference overview
          Hanke, J.H., et al. 1996. J. Biol. Chem. 271, 695.



          Selected Citations
          Lee, J., et al. 2009. Cell Stem Cell 5, 76.


          Citations

          Title
        • Elke Heiss, et al. (2006) Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood in press,.
        • Farahdiba Jafri, et al. (2006) Constitutive ERK1/2 activation by a chimeric neurokinin NK1 receptor-beta-arrestin1 fusion protein: Probing the composition and function of the G protein-coupled receptor 'signalsome'. Journal of Biological Chemistry in press,.
        • Ana Olivera, et al. (2006) IgE-dependent activation of sphingosine kinase 1 and 2 and secretion of sphingosine-1-phosphate requires Fyn kinase and contributes to mast cell responses. Journal of Biological Chemistry 281, 2515-2525.
        • Ellen J. Tisdale and Cristina R. Artalejo. (2006) Src-dependent aPKC/ tyrosine phosphorylation is required for aPKC/ association with Rab2 and glyceraldehyde-3-phosphate dehydrogenase on Pre-golgi intermediates. Journal of Biological Chemistry 281, 8436-8442.
        • Malcolm A. Meyn, et al. (2005) Src family kinase activity is required for murine embryonic stem cell growth and differentiation. Molecular Pharmacology 68, 1320-1330.
        • Justin M. Summy, et al. (2005) AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Molecular Cancer Therapeutics 4, 1900-1911.
        • Jose G. Trevino, et al. (2005) Expression and activity of Src regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Research 65, 7214-7222.
        • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.
        • Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision27-August-2008 RFH
          DescriptionA potent and selective inhibitor of the src family of tyrosine kinases. Its action is similar to PP1. Selectively inhibits p56lck (IC50 = 4 nM), p59fynT (IC50 = 5 nM), and Hck (IC50 = 5 nM) compared to other tyrosine kinases, such as EGF-R (IC50 = 480 nM), JAK2 (IC50 >50 µM) or ZAP-70 (IC50 >100 µM). Also potently inhibits anti-CD3-stimulated tyrosine phosphorylation of human T cells (IC50 = 600 nM).
          FormClear and colorless liquid
          FormulationA 10 mM (1 mg/331 µl) solution of PP2 (Cat. No. 529573) in DMSO.
          Intert gas (Yes/No) Packaged under inert gas
          Chemical formulaC₁₅H₁₆ClN₅
          Structure formulaStructure formula
          Purity≥95% by HPLC
          Storage -20°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot, purge with inert gas, and freeze (-20°C).
          Toxicity Irritant
          ReferencesHanke, J.H., et al. 1996. J. Biol. Chem. 271, 695.



          Selected Citations
          Lee, J., et al. 2009. Cell Stem Cell 5, 76.


          Citation
        • Elke Heiss, et al. (2006) Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood in press,.
        • Farahdiba Jafri, et al. (2006) Constitutive ERK1/2 activation by a chimeric neurokinin NK1 receptor-beta-arrestin1 fusion protein: Probing the composition and function of the G protein-coupled receptor 'signalsome'. Journal of Biological Chemistry in press,.
        • Ana Olivera, et al. (2006) IgE-dependent activation of sphingosine kinase 1 and 2 and secretion of sphingosine-1-phosphate requires Fyn kinase and contributes to mast cell responses. Journal of Biological Chemistry 281, 2515-2525.
        • Ellen J. Tisdale and Cristina R. Artalejo. (2006) Src-dependent aPKC/ tyrosine phosphorylation is required for aPKC/ association with Rab2 and glyceraldehyde-3-phosphate dehydrogenase on Pre-golgi intermediates. Journal of Biological Chemistry 281, 8436-8442.
        • Malcolm A. Meyn, et al. (2005) Src family kinase activity is required for murine embryonic stem cell growth and differentiation. Molecular Pharmacology 68, 1320-1330.
        • Justin M. Summy, et al. (2005) AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Molecular Cancer Therapeutics 4, 1900-1911.
        • Jose G. Trevino, et al. (2005) Expression and activity of Src regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Research 65, 7214-7222.
        • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.